Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $508,856 - $721,795
30,507 Added 102.62%
60,234 $1 Million
Q2 2023

Aug 14, 2023

BUY
$18.02 - $29.36 $1,333 - $2,172
74 Added 0.25%
29,727 $821,000
Q1 2023

May 08, 2023

SELL
$10.78 - $25.38 $184,930 - $435,393
-17,155 Reduced 36.65%
29,653 $682,000
Q4 2022

Feb 13, 2023

BUY
$7.36 - $11.17 $344,506 - $522,845
46,808 New
46,808 $510,000
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $197 - $714
28 New
28 $1,000
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $2.31 Million - $4.87 Million
-131,282 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $897,007 - $3.44 Million
69,267 Added 111.69%
131,282 $2.33 Million
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $1.59 Million - $2.78 Million
62,015 New
62,015 $2.78 Million
Q1 2021

May 13, 2021

SELL
$19.02 - $31.15 $817,707 - $1.34 Million
-42,992 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$18.49 - $25.13 $792,980 - $1.08 Million
42,887 Added 40844.76%
42,992 $867,000
Q3 2020

Nov 12, 2020

BUY
$15.19 - $22.4 $1,594 - $2,352
105 New
105 $2,000
Q3 2019

Nov 14, 2019

SELL
$9.41 - $16.56 $2,860 - $5,034
-304 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$8.98 - $12.96 $1,167 - $1,684
130 Added 74.71%
304 $4,000
Q1 2019

May 10, 2019

BUY
$6.5 - $13.77 $1,131 - $2,395
174 New
174 $2,000
Q3 2018

Nov 13, 2018

SELL
$6.82 - $11.26 $86,491 - $142,799
-12,682 Closed
0 $0
Q2 2018

Aug 10, 2018

SELL
$5.99 - $9.1 $306,921 - $466,274
-51,239 Reduced 80.16%
12,682 $85,000
Q1 2018

May 09, 2018

BUY
$8.46 - $23.08 $393,356 - $1.07 Million
46,496 Added 266.84%
63,921 $549,000
Q4 2017

Feb 14, 2018

BUY
$14.47 - $20.8 $252,139 - $362,440
17,425
17,425 $0

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.